resource-symbol

Alzheimer's Disease-Related Quality of Life (ADRQL)

Black Betty S; Kasper Judith D; Rabins Peter V

Distributed by Mapi Research Trust

Distributed by Mapi Research Trust

default distrib
 

Basic description

Developed in 1999

Revised in 2009 (40-item version recommended by the author)

Authors

Black Betty S; Kasper Judith D; Rabins Peter V

Copyright
ADRQL© 1997, 2009 by Peter V. Rabins, M.D. Judith D. Kasper, Ph.D. and Betty S. Black, Ph.D
Objective
To evaluate treatment interventions in Alzheimer's Disease
Therapeutic area
  • Nervous System Diseases
  • Mental Disorders
Therapeutic indication

Alzheimer Disease

Type of Clinical Outcome Assessment (COA)
  • ObsRO ObsRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Original version:

Rabins Peter V, Kasper Judith D, Kleinman l et al. Concepts and methods in the development of the ADRQL : an instrument for assessing health-related quality of life in persons with Alzheimer’s disease. Journal of Mental Health and Aging, 1999;5,1: 33-48 (abstract)

Black BS, Rabins PV, & Kasper JD. Alzheimer Disease Related Quality of Life User’s Manual. Baltimore, Maryland: DEMeasure. 2000

Rabins PV. Measuring quality of life in persons with dementia. Int Psychogeriatr. 2000;12(suppl.1):47-9 (abstract)

Revised version:

Kasper JD, Black BS, Shore AD, Rabins PV. Evaluation of the validity and reliability of the Alzheimer Disease-related Quality of Life Assessment Instrument. Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):275-84 (Full text article)


Contact and conditions of use

Authors

Black Betty S; Kasper Judith D; Rabins Peter V

- Peter V Rabins, MD, MPH
John Hopkins University
School of Medicine
Dept of Psychiatry
Professor, Psychiatry and Behavioral Sciences
East Baltimore Campus
600 N. Wolfe Street
Baltimore, MD 21287-7279
USA
Phone: +1 (410) 955-6736
Fax: +1 (410) 614-1094
E-mail: pvrabins@jhmi.edu

Peter V Rabins Publications (PubMed)

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Non-Commercial Users

If you do not receive specific funding for your study, you may download the questionnaire directly:

  1. Log in or Register for free
  2. Click the 'Online distribution' tab in the left menu bar and follow the instructions

Tutorials are available on our FAQs.

Commercial Users

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. In order to accelerate the process, you may attach the User Agreement (even if not finalized) to your online request. Click the link below for the user agreement template.
  4. Our PROVIDE team will get back to you with the needed information in a timely manner

Access fees

ROYALTY FEES* Commercial users Cost per study 10 000 USD
Cost per language 500 USD
Funded academic research Cost per study Free
Cost per language Free
Not funded academic users Cost per study Free
Cost per language Free
DISTRIBUTION FEES* Commercial users Cost per study 700 €
Cost per language 300 €
Funded academic research Cost per study 300 €
Cost per language 50 €
Not funded academic users Cost per study Free
Cost per language Free

* Excluding VAT
Commercial users: Industry, CRO, any for-profit companies
Funded Academic research: Projects receiving funding from commerce, government, EU or registered charity. Funded academic research– sponsored by industry fits the “commercial users” category.
Not funded academic users, individual medical practice: Projects are not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds

The Owner, Dr. Rabins Peter V., as defined in section 1.02 may be subject to the laws of the United States including without limitation the United States Affordable Care Act of 2010 and specifically the Physician Payments Sunshine Act (the “US Sunshine Act”). Payments made directly to the Owner or through MRT may apply as Royalty Fees under the US Sunshine Act if the User is also subject to the laws as a medical device and drug manufacturers (“Applicable Manufacturers”) or group purchasing organizations (“GPOs”) that commercialize the medical device or drug in the USA.  The User acknowledges that the User may be required to report the Royalty Fees the appropriate party pursuant to the US Sunshine Act. Please consult www.CMS.govfor more information on the Sunshine Act or contact MRT.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Online distribution

For Non-Funded Academic Studies

The following licensing process is restricted to academic users:

  • Who do not receive specific funding for their study
  • Who intend to use the questionnaire in individual clinical practice or research study

Should you not correspond to this category of users, please send us a request.

Note: This site aims at providing you with the original version and existing translations of the questionnaire. However some modules/versions may not be downloadable in the language you need.

Login

To access this section, please complete a client account.

Languages

Original language(s)

  • English for the USA

Translations

The translations listed may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

ADRQL

Danish for Denmark
French for France
German for Germany
Greek
Japanese for Japan
Spanish for Spain

ADRQL revised

Czech for Czech Republic*
Romanian for Romania*
Russian for Ukraine*
Slovak for Slovakia*
Spanish for the USA*
Ukrainian for Ukraine*
* Performed by Mapi

The author has selected Mapi as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi

Last update: February 2017
For additional information, please submit a request. More information in our FAQs.

YOU MIGHT ALSO BE INTERESTED IN:

PROINSIGHT symbol PROINSIGHT: 1 guidance